You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

selinexor

Showing 26 - 50 of 137
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Acute Myeloid Leukemia, AML Trial in Tampa (Selinexor, Daunorubicin, Cytarabine)

Completed
  • Leukemia
  • +2 more
  • Selinexor
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 30, 2022

Multiple Myeloma Trial in Tampa (Selinexor, Melphalan, Dexamethasone)

Completed
Has Results
  • Multiple Myeloma
  • Selinexor
  • +4 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Nov 2, 2022

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, Selinexor-VRD)

Recruiting
  • Multiple Myeloma
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 12, 2023

Glioblastoma, Glioma Trial in Denmark, Netherlands, United States (Selinexor)

Terminated
Has Results
  • Glioblastoma
  • Glioma
  • Selinexor
  • Boston, Massachusetts
  • +5 more
Jan 24, 2023

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Selinexor
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

Multiple Myeloma Trial in Beijing, Qingdao (SPD:Selinexor Oral Tablet, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
  • Beijing, Beijing, China
  • +1 more
Jul 26, 2022

Endometrial Cancer Trial in Israel, United States (Selinexor, Matching Placebo for selinexor)

Recruiting
  • Endometrial Cancer
  • Selinexor
  • Matching Placebo for selinexor
  • Miami Beach, Florida
  • +6 more
Jan 31, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor

Recruiting
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • +3 more
  • Choline Salicylate
  • Selinexor
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Dec 5, 2022

Sarcoma,Soft Tissue Trial in Spain (Selinexor 20 MG, Gemcitabine)

Recruiting
  • Sarcoma,Soft Tissue
  • Tenerife, Canarias, Spain
  • +10 more
Oct 27, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023

Multiple Myeloma Trial in Zhengzhou, Wuhan, Xi'an (Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin)

Recruiting
  • Multiple Myeloma
  • Selinexor (80mg/d)
  • +4 more
  • Zhengzhou, Henan, China
  • +4 more
Aug 16, 2022

Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

Not yet recruiting
  • Multiple Myeloma at First Relapse
    • (no location specified)
    Sep 27, 2022

    Amyloid, Amyloidosis, AL Amyloidosis Trial in New York (Selinexor, Dexamethasone)

    Suspended
    • Amyloid
    • +2 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    May 17, 2022

    Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Leiomyosarcoma Trial in Toronto (Selinexor)

    Recruiting
    • Soft Tissue Sarcoma
    • +3 more
    • Selinexor
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Apr 7, 2022

    AML, Adult Trial in Hangzhou, Shanghai, Wuhan (Selinexor, Azacitidine, Venetoclax)

    Not yet recruiting
    • AML, Adult
    • Selinexor
    • +2 more
    • Hangzhou, China
    • +3 more
    Feb 12, 2023

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

    Withdrawn
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Elotuzumab, Selinexor, and Dexamethasone (ESd)
    • (no location specified)
    Apr 27, 2022

    Multiple Myeloma Trial in Guangzhou (Selinexor, Bortezomib, Lenalidomide)

    Recruiting
    • Multiple Myeloma
    • Selinexor
    • +3 more
    • Guangzhou, Guangdong, China
    • +3 more
    Aug 16, 2022

    Chemo-Induced Thrombocytopenia Trial (Hetrombopag)

    Not yet recruiting
    • Chemotherapy-Induced Thrombocytopenia
    • (no location specified)
    Jul 24, 2023

    Extramedullary Multiple Myeloma Trial in Wuhan (Selinexor, CT103A)

    Recruiting
    • Extramedullary Multiple Myeloma
    • Wuhan, Hu Bei, China
      Tongji Hospital, Tongji Medical College, Huazhong University of
    May 17, 2022

    Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors Trial in United States (Selinexor)

    Recruiting
    • Wilms Tumor
    • +6 more
    • Selinexor
    • Los Angeles, California
    • +10 more
    Aug 2, 2023

    MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype Trial (Selinexor, Temozolomide)

    Not yet recruiting
    • MGMT-Methylated Glioblastoma
    • Recurrent Glioblastoma, IDH-Wildtype
    • (no location specified)
    Jun 28, 2022

    Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma Trial in Sacramento

    Recruiting
    • Advanced Urothelial Carcinoma
    • +3 more
    • Pembrolizumab
    • Selinexor
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Jun 28, 2022

    Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)

    Recruiting
    • Multiple Myeloma
    • Selinexor
    • +4 more
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Mar 3, 2022

    Gliosarcoma, Newly Diagnosed, Glioblastoma Trial run by the National Cancer Institute (NCI) (Selinexor, Temozolomide, Generic

    Recruiting
    • Gliosarcoma
    • +2 more
    • Selinexor
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 7, 2022